

Bibliography for Molecular Breast Imaging (MBI/BSGI)
July 2014

1. Yoon HJ, Sung SH, Moon BI, Kim BS. Invasive Ductal Carcinoma Arising From Dense Accessory Breast Visualized With 99mTc-MIBI Breast-Specific γ Imaging. *Clin Nucl Med*. 2014 Aug;39(8):717-20. doi: 10.1097/RLU.0000000000000332.
2. Park JY, Yi SY, Park HJ, Kim MS, Kwon HJ, Park NH, Moon SY. Breast-specific gamma imaging: correlations with mammographic and clinicopathologic characteristics of breast cancer. *AJR Am J Roentgenol*. 2014 Jul;203(1):223-8. doi: 10.2214/AJR.13.11566.
3. Johnson N, Sorenson L, Bennetts L, Winter K, Bryn S, Johnson W, Glissmeyer M, Garreau J, Blanchard D. Breast-specific gamma imaging is a cost effective and efficacious imaging modality when compared with MRI. *Am J Surg*. 2014 May;207(5):698-701; discussion 701. doi: 10.1016/j.amjsurg.2013.12.015. Epub 2014 Mar 12.
4. McPeak PR. Advancements in molecular breast imaging. *Radiol Technol*. 2014 May-Jun;85(5):523M-538M; quiz 539M-541M.
5. Lee HS, Ko BS, Ahn SH, Son BH, Lee JW, Kim HJ, Yu JH, Kim SB, Jung KH, Ahn JH, Cha JH, Kim HH, Lee HJ, Song IH, Gong G, Park SH, Lee JJ, Moon DH. Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients. *Breast Cancer Res Treat*. 2014 May;145(1):91-100. doi: 10.1007/s10549-014-2920-z. Epub 2014 Mar 27.
6. Kim MY, Choi N, Ko SM, Chung HW. Background uptake of breast-specific gamma imaging: correlation with mammographic breast density and background enhancement of breast MRI. *Clin Imaging*. 2014 May-Jun;38(3):255-8. doi: 10.1016/j.clinimag.2013.05.010. Epub 2014 Jan 22.
7. Park KS, Chung HW, Yoo YB, Yang JH, Choi N, So Y. Complementary role of semiquantitative analysis of breast-specific gamma imaging in the diagnosis of breast cancer. *Am J Roentgenol*. 2014 Mar;202(3):690-5.
8. Pinker K, Helbich TH, Magometschnigg H, Fueger B, Baltzer P. Molecular breast imaging. An update. *Radiologe*. 2014 Mar;54(3):241-53. doi: 10.1007/s00117-013-2580-8. German.
9. Rechtman LR, Lenihan MJ, Lieberman JH, Teal CB, Torrente J, Rapelyea JA, Brem RF. Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. *Am J Roentgenol*. 2014 Feb;202(2):293-8.
10. Fowler AM. A molecular approach to breast imaging. *J Nucl Med*. 2014 Feb;55(2):177-80. doi: 10.2967/jnumed.113.126102. Epub 2014 Jan 16. Review.
11. Tan H, Jiang L, Gu Y, Xiu Y, Han L, Wu P, Zhang H, Shi H. Visual and semi-quantitative analyses of dual-phase breast-specific gamma imaging with Tc-99m-sestamibi in detecting primary breast cancer. *Ann Nucl Med*. 2014 Jan;28(1):17-24.
12. Schillaci O, Spanu A, Danieli R, Madeddu G. Molecular breast imaging with gamma emitters. *Q J Nucl Med Mol Imaging*. 2013 Dec;57(4):340-51.
13. Kim JS, Lee SM, Cha ES. The diagnostic sensitivity of dynamic contrast-enhanced magnetic resonance imaging and breast-specific gamma imaging in women with calcified and non-calcified DCIS. *Acta Radiol*. 2013 Sep 16;55(6):668-675. [Epub ahead of print]
14. Edwards C, Williams S, McSwain AP, Damle S, Rapelyea JA, Downs K, Torrente J, Sambamurthy A, Brem RF, Teal CB. Breast-specific gamma imaging influences surgical management in patients with breast cancer. *Breast J*. 2013 Sep-Oct;19(5):512-9.

15. Park JS, Lee AY, Jung KP, Choi SJ, Lee SM, Kyun Bae S. Diagnostic Performance of Breast-Specific Gamma Imaging (BSGI) for Breast Cancer: Usefulness of Dual-Phase Imaging with (99m)Tc-sestamibi. *Nucl Med Mol Imaging*. 2013 Mar;47(1):18-26. doi: 10.1007/s13139-012-0176-2. Epub 2012 Oct 13.
16. Sun Y, Wei W, Yang HW, Liu JL. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. 2013 Feb;40(3):450-63.
17. Spanu A, Sanna D, Chessa F, Cottu P, Manca A, Madeddu G. Breast scintigraphy with breast specific gamma-camera in the detection of ductal carcinoma in situ: a correlation with mammography and histology subtype. *J Nucl Med*. 2012 Oct;53(10):1528-33,doi:10.2967/jnumed. 112.103010. Epub 2012 Aug 21
18. Kim BS, Moon BI, Cha ES. A comparative study of breast-specific gamma imaging with the conventional imaging modality in breast cancer patients with dense breasts. *Ann Nucl Med*. 2012 Aug 26. [Epub ahead of print]
19. Lee A, Chang J, Lim W, Kim BS, Lee JE, Cha ES, Moon BI. Effectiveness of Breast-Specific Gamma Imaging (BSGI) for Breast Cancer in Korea: A Comparative Study. *Breast J*. 2012 Sep;18(5):453-8.
20. Ling CM, Coffey CM, Rapelyea JA, Torrente J, Teal CB, McSwain AP, Brem RF. Breast-specific gamma imaging in the detection of atypical ductal hyperplasia and lobular neoplasia. *Acad Radiol*. 2012 Jun;19(6):661-6.
21. Spanu A, Sanna D, Chessa F, Manca A, Cottu P, Fancellu A, Nuvoli S, Madeddu G. The clinical impact of breast scintigraphy acquired with a breast specific γ -camera (BSGC) in the diagnosis of breast cancer: Incremental value versus mammography. *Int J Oncol*. 2012 Aug;41(2):483-9.
22. Tadwalkar RV, Rapelyea JA, Torrente J, Rechtman LR, Teal CB, McSwain AP, Donnelly C, Kidwell AB, Coffey CM, Brem RF. Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade. *Br J Radiol*. 2012 Jun;85(1014):e212-6. doi: 10.1259/bjr/34392802. Epub 2011 Jun 28.
23. Wahner-Roedler DL, Boughey JC, Hruska CB, Chen B, Rhodes DJ, Tortorelli CL, Maxwell RW, Cha SS, O'Connor MK. The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot study. *Clin Nucl Med* 2012 Apr;37(4):344-50. doi:10.1097/RLU.0b013e31824437b3
24. Siegal E, Angelakis E, Morris P, Pinkus E. Breast molecular imaging: a retrospective review of one institutions experience with this modality and analysis of its potential role in breast imaging decision making. *Breast J*. 2012 Mar-Apr;18(2):111-7.
25. Keto JL, Kirstein L, Sanchez DP, Fulop T, McPartland L, Cohen I, Boolbol SK. MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in-situ: a prospective head-to-head trial. *Ann Surg Oncol*. 2012 Jan;19(1):249-52.
26. Kim BS. Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with dense breast: a comparative study with MRI. *Ann Nucl Med*. 2012 Feb;26(2):131-7.
27. Weigert J, Bertrand M, Stern L, Kieper D. Results of a Multicenter Patient Registry to Determine the Clinical Impact of Breast-Specific Gamma Imaging, a Molecular Breast Imaging Technique. *AJR*:198, January 2012.
28. Kessler R, et al. Negative Predictive Value of Breast-Specific Gamma Imaging in Low Suspicion Breast Lesions: A Potential Means for Reducing Benign Biopsies. *The Breast Journal*, 2011 1–3
29. Brem RF, Shahan C, Rapleyea JA, Donnelly CA, Rechtman LR, Kidwell AB, Teal CB, McSwain A, Torrente J. Detection of occult foci of breast cancer using breast-specific gamma imaging in women with one mammographic or clinically suspicious breast lesion. *Acad Radiol*. 2010 Jun;17(6):735-43.

30. Werner J, Rapelyea JA, Yost KG, Brem RF. Quantification of radio-tracer uptake in axillary lymph nodes using breast specific gamma imaging (BSGI): benign radio-tracer extravasation versus uptake secondary to breast cancer. *Breast J*. 2009 Nov-Dec;15(6):579-82.
31. Silverstein M, Recht A, Lagios MD, Bleiweiss I, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman R, Klimberg S, Kuske R, Levine G, Linver M, Rafferty E, Rugo H, Schilling K, Tripathy D, Whitworth PW, Willey SC. Image-Detected Breast Cancer: State-of-the-Art Diagnosis and Treatment. *American College of Surgeons Consensus III*. 2009. ISSN 1072-7515/09
32. Killelea B, Gillego A, Kirstein LJ, et al. George Peters Award: How does breast-specific gamma imaging affect the management of patients with newly diagnosed breast cancer? *The American Journal of Surgery* (2009) 198, 470 – 474.
33. Brem R, et al. Breast Specific Gamma Imaging in Women with One Suspicious or Cancerous Breast Lesion. Invasive Lobular Carcinoma: Detection with Mammography, Ultrasound, Magnetic Resonance Imaging, and Breast-specific Gamma Imaging (BSGI). *The American Journal of Roentgenology*, 192, February 2009; Pages 379 – 383.
34. Zhou M, Johnson N, Gruner S, Ecklund GW, Muenier P, Bryn S, Green G, et al. Clinical Utility of Breast Specific Gamma Imaging For Evaluating Disease Extent in the Newly Diagnosed Breast Cancer Patient. *The American Journal of Surgery*, Vol 197, No 2, February 2009.
35. Jones EA, Phan T, Blanchard DA, Miley A. Breast-Specific Gamma-Imaging: Molecular Imaging of the Breast Using ^{99m}Tc-Sestamibi and a Small-Field-of-View Gamma-Camera. *J Nucl Med Technol* 2009; 37:201–205.
36. Brem R, Floerke A, Rapelyea J, Teal C, Kelly T, Mathur V. Breast Specific Gamma Imaging as an Adjunct Imaging Modality for the Diagnosis of Breast Cancer. *Radiology*. 2008; 247(3):651-57.
37. Zhou M, Johnson N, Blanchard D, Bryn S, Nelson J. Real-world application of breast-specific gamma imaging, initial experience at a community breast center and its potential impact on clinical care. *The American Journal of Surgery* (2008) 195, 631–635.
38. Brem R, Petrovitch I, Rapelyea J, Young H, Teal C, Kelly T. Breast-Specific Gamma Imaging with ^{99m}Tc-Sestamibi and Magnetic Resonance Imaging in the Diagnosis of Breast Cancer—A Comparative Study. *The Breast Journal*. Volume 13 Issue 5 Page 465-469, September 2007.
39. Brem R, Fishman M, Rapelyea JA. Detection of Ductal Carcinoma in Situ with Mammography, Breast Specific Gamma Imaging, and Magnetic Resonance Imaging: A Comparative Study. *Academic Radiology* Volume 14, Issue 8, Pages 945-950. August 2007.
40. O'Connor MK, Phillips SW, Hruska CB, Rhodes DJ, Collins DA. Molecular breast imaging: advantages and limitations of a scintimammographic technique in patients with small breast tumors. *Breast J*. 2007 Jan-Feb;13(1):3-11.
41. Gommans GM, van der Zant FM, van Dongen A, Boer RO, Teule GJ, de Waard JW. (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography. *Eur J Surg Oncol*. 2007 Feb;33(1):23-7. Epub 2006 Nov 27.
42. Lumachi F, Tregnaghi A, Ferretti G, Povolato M, Marzola MC, Zucchetta P, Cecchin D, Bui F. Accuracy of ultrasonography and ^{99m}Tc-sestamibi scintimammography for assessing axillary lymph node status in breast cancer patients. A prospective study. *Eur J Surg Oncol*. 2006 Nov; 32(9):933-6. Epub 2006 Jun 21.
43. Cox C. Et al. Localization of an Occult Primary Breast Cancer with Technetium-99m Sestamibi Scan and an Intraoperative Gamma Probe. *Cancer Control Journal: Imaging in Oncology*. 2006 Feb. <http://www.moffitt.usf.edu/pubs/ccj/v3n5/dept3.html>.

44. Hussain R, Buscombe JR. A meta-analysis of scintimammography: an evidence-based approach to its clinical utility. *Nucl Med Commun*. 2006 Jul;27(7):589-94.
45. Rhodes DJ, O'Connor MK, Phillips SW, Smith RL, Collins DA. Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. *Mayo Clin Proc*. 2005;80:24-30.
46. Brem R, Rapelyea J, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in Women at High Risk for Breast Cancer. *Radiology*. 2005; 237:274-280.
47. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA. Residual tumor uptake of [(99m)Tc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. *Cancer*. 2005 Feb 15; 103(4):680-8.
48. Taillefer R, et al. Clinical Applications of Scintimammography. *Sem Nuc Med*. 2005; 35:100-15.
49. Rhodes DJ, O'Connor MK, Phillips SW, Smith RL, Collins DA. Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. *Mayo Clin Proc*. 2005 Jan;80(1):24-30.
50. Kieper D, Brem R, Hoeffler R, Keppel C, Wymer D. Detecting Infiltrating Lobular Carcinoma Using Scintimammographic Breast Specific Gamma Imaging. *Physica Medica*, Vol. XXI, Supplement 1, 2005.
51. Massardo T, Alonso O, Llamas-Ollier A, et al. Planar Tc99m – sestamibi scintimammography should be considered cautiously in the axillary evaluation of breast cancer protocols: results of an international multicenter trial. *BMC Nucl Med* 2005;5:4.
52. Fondrinier E, Muratet JP, Anglade E. Clinical experience with 99mTc-MIBI scintimammography in patients with breast calcifications. *Breast* 2004;13:316-20.
53. Bekis R, Derebek E, Balci P, Kocdor MA, Degirmenci B, Canda T, Durak H. 99mTc sestamibi scintimammography. Screening mammographic non-palpable suspicious breast lesions: preliminary results. *Nuklearmedizin*. 2004 Feb;43(1):16-20.
54. Bongers V, Perre C, de Hooge P. The use of scintimammography for detecting the recurrence of loco-regional breast cancer: histopathologically proven results. *Nucl Med Commun*. 2004 Feb; 25(2):145-9.
55. Coover LR, Caravaglia G, Kuhn P. Scintimammography with dedicated breast camera detects and localizes occult carcinoma. *J Nucl Med*. 2004 Apr;45(4):553-8.
56. Schillaci O, Buscombe JR. Breast scintigraphy today: indications and limitations. *Eur J Nucl Med Mol Imaging*. 2004 Jun;31 Suppl 1:S35-45. Epub 2004 Apr 23.
57. Kieper D, Majewski S, Kross B, et al. Optimization of breast imaging procedure with dedicated compact gamma cameras. *Nuclear Instruments and Methods in Physics Research 2003 (Sect A 497):168-73*.
58. Babuccu O, Peksoy I, Kargi E, Hosnuter M, Ozdemir H Gundogdu S, et al. the value of scintimammography in reduction mammoplasties: a preliminary study. *Aesthetic Plast Surg*. 2003;27(4):296-300.
59. Brem R, Kieper D. Rapelyea J. Majewski S. Evaluation of a high-resolution, breast-specific, small-field-of-view gamma camera for the detection of breast cancer. *Nucl Instr and Meth*. 2003; 497(1):168 – 173.
60. Chen J, Wu H, Zhou J, Hu J. Using Tc-99m MIBI scintimammography to differentiate nodular lesions in breast and detect axillary lymph node metastases from breast cancer. *Chin Med J (Engl)*. 2003 Apr;116(4):620-4.

61. Kieper D, Green TD, Hoefler R, Keppel C, Wymer DC, Weisenberger AG, Welch B. Data analysis methods for a small field-of-view combined scintimammography/digital X-ray system in breast lesion management. *Nucl Instr and Meth A*. 2003; 497: 135-140.
62. Krishnaiah G, Sher-Ahmed A, Ugwu-Dike M, Regan P, Singer J, Totoonchie A, Spiegler E, Sardi A. Technetium-99m sestamibi scintimammography complements mammography in the detection of breast cancer. *Breast J*. 2003 Jul-Aug;9(4):288-94.
63. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. *J Nucl Med*. 2003; 44:1806-1814.
64. Peng NJ, Chang HT, Tsay DG, Liu RS. Technetium-99m-sestamibi scintimammography to detect breast cancer in patients with paraffinomas or siliconomas after breast augmentation. *Cancer Biother Radiopharm*. 2003 Aug;18(4):573-80.
65. Sampalis F.S. et al. International prospective evaluation of scintimammography with 99mTechnetium sestamibi. *Amer Journ Surg*. 2003. 185 544–549.
66. Liberman M, Sampalis F, Mulder DS, Sampalis JS. Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. *Breast Cancer Res Treat* 2003;80:115-26.
67. Palmedo H. What can we expect from MDR breast cancer imaging with sestamibi. *J Nucl Med* 2002;43:526-529.
68. Sciuto R, Pasqualoni R, Bergomi S, et al. Prognostic value of 99,Tc-setamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. *J Nucl Med* 2002;43:745-51.
69. Wang HC, Sun SS, Kao A, Lin CC, Lee CC. Comparison of technetium-99m methoxyisobutylisonitrile scintimammography and ultrasonography in the diagnosis of breast cancer in patients with mammographically dense breast. *Cancer Invest*. 2002; 20(3):318-23.
70. Chen YS, Wang WH, Chan T, Sun SS, Kao A. A review of the cost-effectiveness of Tc-99m sestamibi scintimammography in diagnosis of breast cancer in Taiwanese women with indeterminate mammographically dense breast. *Surg Oncol*. 2002 Nov; 11(3):151-5.
71. Lumachi F, Zucchetta P, Marzola MC, Ferretti G, Povolato M, Paris MK, Brandes AA, Bui F. Positive predictive value of 99mTc sestamibi scintimammography in patients with non-palpable, mammographically detected, suspicious, breast lesions. *Nucl Med Commun*. 2002 Nov; 23(11):1073 - 8.
72. Brem RF, Schoonjans JM, Kieper DA, Majewski S, Goodman S, Civelek C. High-resolution scintimammography: a pilot study. *J Nucl Med*. 2002; 43:909-915.
73. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. *J Nucl Med*.2002;43:500-509.
74. Sallomi DF, Howlett DC, Ementon RA, Marchbank ND, Anderson HJ, Allan SM. Scintimammography: a pictorial review of the variable normal, post surgical and pathological appearances. *Breast*. 2002 Feb; 11(1):41-8.
75. Cayre A, Cachin F, Maublant J, et al. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. *Int J Oncol* 2002;20:1049-55.
76. Mubashar M, Harrington KJ, Chaudhary KS, et al. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. *J Nucl Med* 2002;43:519-25.
77. Khalkhali I, Baum JK, Villanueva-Meyer J, et al. ^{99m}Tc sestamibi breast imaging for the examination of patients with dense fatty breasts: multicenter study. *Radiology* 2002;222:149-55.

78. Lumachi F, Ferretti G, Povolato M, et al. Usefulness of ^{99m}Tc-sestamibi scintimammography in suspected breast cancer and in axillary lymph node metastases detection. *Eur J Surg Oncol* 2001;27:256-9.
79. Imbriaco M, Del Vecchio S, Riccardi A, et al. Scintimammography with ^{99m}Tc-MIBI versus dynamic MRI for non-invasive characterization of breast masses. *Eur J Nucl Med* 2001;28:56-63
80. Prats E, Banzo J, Meroño E, et al. ^{99m}Tc-MIBI scintimammography as a complement to mammography in patients with suspected breast cancer. A multicentre experience. *Breast* 2001;10:109-16.
81. Majewski S. Kieper D. Curran E. Keppel C. Kross B. Palumbo A. Popov V. Weisenberger A.G. Welch B. Wojcik R. Williams M.B. Goode A.R. Moore M. Zang G. Optimization of dedicated scintimammography procedure using detector prototypes and compressible phantoms. *IEEE Transactions of Nuclear Science Conference Volume 41*. June 2001.
82. Marini C, Cilotti A, Traino AC, et al. Tc ^{99m}-sestamibi scintimammography in the differentiation of benign and malignant breast microcalcifications. *Breast* 2001; 10:306 –312.
83. Polan RL, Klein BD, Richman RH. Scintimammography in patients with minimal mammographic or clinical findings. *Radiographics* 2001;21:641-53.
84. Cwikla JB, Buscombe JR, Holloway B, et al. Can scintimammography with ^{99m}Tc-MIBI identify multifocal and multicentric primary breast cancer? *Nucl Med Commun* 2001; 22:1287–1293.
85. Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J. Metastatic axillary lymph node technetium-^{99m}-MIBI imaging in primary breast cancer. *J Nucl Med*, Vol 39, Issue 3 459-464, 2001
86. Garibaldi F, Cisbani E, Cusanno F, Iommi R, Urciuoli GM, Pani R, Pellegrini R, Scafe R, Indovina L, Cinti MN, Trotta G. Optimization of compact gamma cameras for breast imaging. *Nucl. Instr. & Meth. in Phys Res. Sec. A* Vol. 471, no. 1, p. 222, 2001.
87. Kao C-H, Tsai S-H, Liu T-J, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-^{99m} methoxybutylisonitrile scintimammography findings. *Cancer Res* 2001;61:1412-14.
88. Buscombe JR, Cwikla JB, Holloway B, Hilson AJW. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. *J Nucl Med* 2001;42:3-8.
89. Alonso O, Massardo T, Delgado LB, et al. Is ^{99m}Tc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? *J Nucl Med* 2001;42:1614-1621.
90. Khalkhali I, Villanueva-Meyer J, Edell SL, et al. Diagnostic accuracy of ^{99m}Tc-sestamibi breast imaging: multicenter trial results. *J Nucl Med* 2000;41:1973-79.
91. Chen S. Liu W. Mao Y. Zhu W. Yao Z. et al. ^{99m}Tc-MIBI and ^{99m}Tc-MDP scintimammography for detecting breast carcinoma. *Chin Med J* 2000; 113(5):400-403.
92. Mulero F, Nicolas F, Castellon MI, Fuentes T, et al. [^{99m}Tc-mibi scintigraphy compared to mammography in the diagnosis of breast cancer in dense, operated and young women breasts. *Rev Esp Med Nucl*. 2000; 19(5):344-349.
93. Cwikla JB, Buscombe JR, Hilson AJ. Detection of DCIS using ^{99m}Tc-MIBI scintimammography in patients with suspected primary breast cancer, comparison with conventional mammography. *Nucl Med Rev Cent East Eur*. 2000; 3(1):41-5.
94. Stuntz ME, Khalkhali I, Kakuda JT, et al. Scintimammography. *Seminars In Breast Disease*. 2000;2:97-106

95. Pappo I, Horne T, Weissberg D, et al. The usefulness of MIBI scanning to detect underlying carcinoma in women with acute mastitis. *Breast* 2000;6:126-9.
96. Paz A, Melloul M, Cytron S, et al. The value of early and double phase ^{99m}Tc-sestamibi scintimammography in the diagnosis of breast cancer. *Nucl Med Commun* 2000;21:341-8
97. Allen MW, Hendi P, Schwimmer J, Bassett L, Gambhir SS. Decision analysis for the cost effectiveness of sestamibi scintimammography in minimizing unnecessary biopsies. *Q J Nucl Med*. 2000 Jun;44(2):168-85.
98. Cutrone JA, Khalkhali I, Yospur LS, et al. Tc-99m sestamibi scintimammography for the evaluation of breast masses in patients with radiographically dense breasts. *Breast* 1999;5:383-88.
99. Howarth D, Sillar R, Clark D, Lan L. Technetium-99m sestamibi scintimammography: the influence of histopathological characteristics, lesion size and the presence of carcinoma in situ in the detection of breast carcinoma. *Eur J Med* 1999;26:1475-81.
100. Taillefer R. The role of 99m sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. *Sem Nucl Med* 1999; 29:16-40.
101. Scopinaro F, Pani R, de Vincentis G, Soluri A, Pellegrini R, Porfiri LM, High-resolution scintimammography improves the accuracy of Tc-99m methoxyisobutylisonitrile scintimammography: use of a new dedicated gamma camera. *Eur. J. Nucl. Med.* vol. 26, pp.1279-1288, 1999.
102. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [Technetium-99m] – sestamibi scintimammography. *Cancer*. 1999; 85:2410-2423.
103. Tolmos J, Cutrone JA, Wang B, et al. Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography. *J Natl Cancer Inst* 1998;90:846-9.
104. Taillefer R, Robidoux A, Turpin S, et al. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. *J Nucl Med* 1998;39:459-64.
105. Mekhmandarov S, Sandbank J, Cohen M, et al. Technetium-99m-MIBI scintimammography in palpable and nonpalpable breast lesions. *J Nucl Med* 1998;39:86-91.
106. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxybutylisonitrile: results of a prospective European multicentre trial. *Eur J Nucl Med* 1998;25:375-85.
107. Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. *Nucl Med Commun*. 1997 Aug;18(8):698-709.
108. Del Vecchio SD, Ciarmello A, Pace P, et al. Fractional retention of technetium-99m-sestamibi as an index of p-glycoprotein expression in untreated breast cancer patients. *J Nucl Med* 1997;38:1348-51.
109. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, Biersack HJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. *Eur J Nucl Med*. 1997 Sep;24(9):1138-45.
110. Tiling R, Sommer H, Pechmann M, Moser R, Kress K, Pfluger T, Tatsch K, Hahn K. Comparison of technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. *J Nucl Med* 1997 Jan;38(1):58-62.
111. Maini CL, Tofani A, Sciuto R, et al. Technetium-99m MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. *J Nucl Med*. 1997;38:1546-1550.
112. Kostakoglu L, Elahi N, Kiratli P, et al. Clinical validation of the influence of p-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. *J Nucl Med* 1997;38:1003-8.

113. Fenlon HM, Phelan NC, O'Sullivan P, Tierney S, Gorey T, Ennis JT. Benign versus malignant breast disease: comparison of contrast-enhanced MR imaging and Tc-99m tetrofosmin scintimammography. *Radiology* 1997 Oct;205(1):214-20.
114. Clifford EJ, Lugo-Zamudio C. Scintimammography in the diagnosis of breast cancer. *Am J Surg* 1996;172:483-6.
115. Tiling R, Khalkhali I, Sommer H, Moser R, Meyer G, Willemsen F, Pfluger T, Tatsch K, Hahn K. Role of technetium-99m sestamibi scintimammography and contrast-enhanced magnetic resonance imaging for the evaluation of indeterminate mammograms. *Eur J Nucl Med* 1997 Oct;24(10):1221-9.
116. Palmedo H, Schomburg A, Grunwald F, Mallmann P, Boldt I, Biersack HJ. Scintimammography with Tc-99m MIBI in patients with suspicion of primary breast cancer. *Nucl Med Biol.* 1996 Aug; 23(6):681- 4.
117. Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. *Radiology* 1995;196:421-6.
118. Pinder SE, Wencyk P, Sibbering DM et al. Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis: associations with other prognostic factors and survival. *Br J Cancer.* 1995;71:146-149.